Welcome to Chinese Journal of Clinical Pharmacology and Therapeutics,Today is Chinese

Chinese Journal of Clinical Pharmacology and Therapeutics ›› 2024, Vol. 29 ›› Issue (10): 1194-1200.doi: 10.12092/j.issn.1009-2501.2024.10.013

Previous Articles    

Research progress of miRNA in asthma: airway inflammation and endotype

BAO Bahu1, LIU Weiying2, YE Yucai1, CHEN Guorong1, SUN Jingzi1, HU Aoyan1   

  1. 1 The First Clinical Medical College of Lanzhou University, Lanzhou 730030, Gansu, China; 2 Department of Respiratory and Critical Care Medicine, Lanzhou University First Hospital, Lanzhou 730030, Gansu, China
  • Received:2023-10-09 Revised:2024-01-15 Online:2024-10-26 Published:2024-09-29

Abstract:

microRNA (miRNA) is a 22nt long single-stranded non-coding RNA that is involved in a variety of physiological and pathological processes. Bronchial asthma is a heterogeneous disease, and airway inflammation is one of the important mechanisms of its pathogenesis. Asthma can be classified into different types based on the different immune mechanisms involved in its pathogenesis, and the mechanism of airway inflammation also varies between different types of asthma.This article reviews the research progress of miRNA in asthma airway inflammation and endotype, and explores the pathogenesis and treatment prospects of miRNA in asthma airway inflammation and endotype.

Key words: asthma, airway inflammation, miRNA, endotype

CLC Number: